DDInter1226 DDInter1631
A potent direct-acting peripheral vasodilator (vasodilator agents) that reduces peripheral resistance and produces a fall in blood pressure.
Safinamide is for the treatment of parkinson's disease. It was approved in Europe in February 2015, and in the United States on March 21, 2017.
Minoxidil {u} (Compound) treats {v} (Disease) hypertension
Minoxidil {u} (Compound) binds {v} (Gene) KCNJ1
Minoxidil {u} (Compound) upregulates {v} (Gene) CDK6
Minoxidil {u} (Compound) is included by {v} (Pharmacologic Class) Arteriolar Vasodilation
Minoxidil {u} may cause a minor interaction that can limit clinical effects when taken with {v} Tadalafil
Minoxidil {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Dexmedetomidine
Minoxidil {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Amitriptyline
Minoxidil {u} may lead to a major life threatening interaction when taken with {v} Guanethidine
Minoxidil {u} may lead to a major life threatening interaction when taken with {v} Guanadrel
Minoxidil (Compound) treats hypertension (Disease)
Minoxidil (Compound) binds KCNJ1 (Gene)
Minoxidil (Compound) upregulates CDK6 (Gene)
Minoxidil (Compound) is included by Arteriolar Vasodilation (Pharmacologic Class)
Minoxidil may cause a minor interaction that can limit clinical effects when taken with Tadalafil
Minoxidil may cause a moderate interaction that could exacerbate diseases when taken with Dexmedetomidine
Minoxidil may cause a moderate interaction that could exacerbate diseases when taken with Amitriptyline
Minoxidil may lead to a major life threatening interaction when taken with Guanethidine
Minoxidil may lead to a major life threatening interaction when taken with Guanadrel